Fig. 1 · Structure

Documents & Downloads

Carbamazepine

Cat. No. A10179 CAS 298-46-4
Carbamazepine is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia.

In Stock

Publications for Carbamazepine

4 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  3. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  4. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Carbamazepine shifted steady-state inactivation of human Naᵥ1.1, Naᵥ1.2, Naᵥ1.3 and Naᵥ1.6 α-subunits toward more negative potentials in HEK293 cells. The fitted EC50 values describe half-maximal inactivation shifts, rather than peak-current inhibition; their differences among isoforms were not significant. These experiments used α-subunits without β-subunits, which limits extrapolation to neuronal channels. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Sodium channel 131 μM

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 22 μM Blockade of human Nav1.7 channel expressed in HEK293 cells by FRET assay [PMID: 18243692]
Hepatocyte EC50 145 μM Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method [PMID: 22815312]
Hepatocyte EC50 26 μM Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method [PMID: 22815312]

Carbamazepine Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Carbamazepine from 3 published references.

Carbamazepine In Vitro Studies

In HEK293 cells expressing human Naᵥ1.7, 300 μM carbamazepine inhibited current by 65% ± 1% with external whole-cell application and by 67% ± 5% when applied directly to the intracellular surface of inside-out patches (mean ± SEM; n = 4 each). Internal whole-cell dialysis produced only a 13% ± 4% decline over 10 min (n = 5). Holding potentials were adjusted for the excision-induced shift in inactivation, making application configuration an essential condition of these results. [2]

Concentration-dependent modulation of four human brain sodium-channel α-subunits

Cell-based study · HEK293 cells stably expressing human Naᵥ1.1, Naᵥ1.2, Naᵥ1.3 or Naᵥ1.6 α-subunits without β-subunits [1]

Carbamazepine shifted steady-state inactivation toward hyperpolarized potentials. Differences among carbamazepine EC50 values were not significant. The α-subunit expression system limits extrapolation to neurons with β-subunits.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.1; not peak-current inhibition IC50. Table sample size in brackets.EC50 134.6 ± 41.3 μM (mean ± SEM; n = 34)[1]
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.2; not peak-current inhibition IC50. Table sample size in brackets.EC50 106.0 ± 30.7 μM (mean ± SEM; n = 37)[1]
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.3; not peak-current inhibition IC50. Table sample size in brackets.EC50 49.2 ± 19.8 μM (mean ± SEM; n = 17)[1]
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.6; not peak-current inhibition IC50. Table sample size in brackets.EC50 116.4 ± 28.5 μM (mean ± SEM; n = 18)[1]
Fitted maximal absolute hyperpolarizing shift of inactivation midpointΔVhmax Naᵥ1.1: 17.2 ± 2.6; Naᵥ1.2: 16.8 ± 2.3; Naᵥ1.3: 9.7 ± 1.5; Naᵥ1.6: 20.5 ± 2.3 mV (mean ± SEM; table n = 34, 37, 17, 18, respectively)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10, 20, 50, 100 and 200 μM
Exposure duration
Each recording protocol lasted 2–2.5 min and was repeated at least twice per control/drug solution; no separate incubation duration specified.
Method
Extracellular application during whole-cell voltage clamp at 20–22°C. Steady-state inactivation used 2500 ms prepulses from −150 to −35 mV followed by a 25 ms step to −10 mV. Control solution before and after drug monitored rundown.
Vehicle
DMSO; Materials reports 0.05% for carbamazepine-containing solutions and no observed DMSO effect on Na+ currents.
Reported limits
No lot/purity reported in the selected Materials paragraph; no Adooq material tested.
Methods and source locations

Compound reported in the paper: Carbamazepine; Compound label in the paper: CBZ

Reported carbamazepine experiment; no salt conversion or validation of SKU A10179 lots.

Results: AED effects on the inactivation properties; Fig. 5B, Table 2; Fig. 1B protocol; Methods: Materials, whole-cell recordings, data analysis

Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.1; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.1 row; Methods: Data analysis

Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.2; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.2 row; Methods: Data analysis

Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.3; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.3 row; Methods: Data analysis

Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.6; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.6 row; Methods: Data analysis

Fitted maximal absolute hyperpolarizing shift of inactivation midpoint: Logistic fit; maximal fitted shift is distinct from observed shift at 200 μM. — Table 2, Carbamazepine ΔVhmax column; Fig. 5B; Results interpretation

Configuration-dependent accessibility of human Naᵥ1.7 channels

Cell-based study · HEK293 cells stably expressing human Naᵥ1.7; whole-cell versus inside-out patch recordings [2]

External whole-cell application and direct application to the intracellular face of excised patches both rapidly inhibited current. Internal whole-cell dialysis produced little decline. Excision shifted inactivation; different holding potentials aligned resting availability. Membrane escape during dialysis remains an explanatory hypothesis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction in sodium current with extracellular whole-cell applicationCurrent inhibition 65% ± 1% (mean ± SEM; n = 4)[2]
Decline in current during internal whole-cell dialysisCurrent decline 13% ± 4% over 10 min (mean ± SEM; n = 5)[2]
Reduction in current with direct internal-surface application in inside-out patchesCurrent inhibition 67% ± 5% (mean ± SEM; n = 4)[2]

Literature-Reported Treatment Conditions

Treatment concentration
300 μM carbamazepine
Exposure duration
Acute external/inside-out perfusion; inside-out block complete within 1–2 s. Internal whole-cell dialysis assessed over 10 min.
Method
Voltage clamp at 21–23°C; pre-drug control and washout. Whole-cell holding potential −75 mV; inside-out −100 mV to account for inactivation shift. Lidocaine and QX-314 comparator experiments assessed application configuration.
Reported limits
Drug supplier, lot, purity and stock solvent not specified in retrieved Materials and Methods. No Adooq lot tested.
Methods and source locations

Compound reported in the paper: Carbamazepine; Compound label in the paper: CBZ

Reported carbamazepine experiment; no salt conversion or validation of SKU A10179 lots.

Results and captions Figs. 1–3; shared electrophysiology methods; Fig. 4 controls; Discussion

Reduction in sodium current with extracellular whole-cell application: 300 μM; 30 ms pulses −75 to −20 mV every 3 s; reversible external block. — Results first subsection; Fig. 1A,D

Decline in current during internal whole-cell dialysis: 300 μM carbamazepine in pipette; same pulse protocol; modest decline is not attributed entirely to drug-specific inhibition. — Results first subsection; Fig. 1B–D

Reduction in current with direct internal-surface application in inside-out patches: 300 μM; 30 ms pulses −100 to −20 mV every 3 s; block complete within 1–2 s and reversed within 2–5 s. Holding potential adjusted for excision-induced inactivation shift. — Results second subsection; Fig. 3A–C and caption

Carbamazepine In Vivo Studies

Single oral carbamazepine doses protected against tonic hindlimb extension in maximal electroshock tests, with reported ED50 values of 9.67 mg/kg in male CF-1 mice and 4.39 mg/kg in Sprague-Dawley rats of both sexes. Testing occurred 0.5 h after dosing in mice and 2 h in rats. These acute, retrospective dose-response data do not establish chronic efficacy or human dose equivalence. [3]

Acute oral carbamazepine dose-response in rodent MES models

Animal study · Male CF-1 mice and Sprague-Dawley rats of both sexes; maximal electroshock seizure endpoint [3]

Carbamazepine protected against tonic hindlimb extension, with reported ED50 values of 9.67 mg/kg in mice and 4.39 mg/kg in rats. Pretreatment intervals differed between species. This retrospective acute experiment does not establish chronic epilepsy control or human dose equivalence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Protection against MES-induced tonic hindlimb extension in male CF-1 miceED50 9.67 mg/kg[3]
Protection against MES-induced tonic hindlimb extension in Sprague-Dawley rats of both sexesED50 4.39 mg/kg[3]

Conditions shared by the study groups

Route
Oral (PO)
Frequency
Single dose
Vehicle
0.5% methylcellulose + 0.2% Tween 80 in deionized water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Mouse CBZ dose-response
3, 6, 10, 20 and 30 mg/kg
Appropriate vehicle-treated group; randomized assignment and blinded seizure scoringDose-dependent protection; ED50 = 9.67 mg/kg. Fig. 1A n by group: vehicle 40; 3 mg/kg 24; 6 mg/kg 16; 10 mg/kg 40; 20 mg/kg 16; 30 mg/kg 8.[3]
Rat CBZ dose-response
1, 2, 3, 5, 8, 10 and 30 mg/kg
Appropriate vehicle-treated group; randomized assignment and blinded seizure scoringDose-dependent protection; ED50 = 4.39 mg/kg. Fig. 1B n by group: vehicle 49; 1 mg/kg 32; 2 mg/kg 8; 3 mg/kg 8; 5 mg/kg 8; 8 mg/kg 8; 10 mg/kg 9; 30 mg/kg 9.[3]
Mouse CBZ dose-response
Model: Male CF-1 mice, 3–7 weeks old
Treatment course: MES test 0.5 h after administration
Reported limits: Retrospective pooled dataset; dose-group n reflects Fig. 1 totals, not number of independent experiments. Rat sex-specific results not presented. ED50 uncertainty not reported with these values.
Rat CBZ dose-response
Model: Sprague-Dawley rats, 5 weeks old, both sexes
Treatment course: MES test 2 h after administration
Reported limits: Retrospective pooled dataset; dose-group n reflects Fig. 1 totals, not number of independent experiments. Rat sex-specific results not presented. ED50 uncertainty not reported with these values.
Methods and source locations

Compound reported in the paper: Carbamazepine; Compound label in the paper: CBZ

Reported carbamazepine experiment; no salt conversion or validation of SKU A10179 lots.

Results first CBZ paragraph; Fig. 1A,B; Fig. 2A dose-response ED50 labels; Methods 4.1–4.3, 4.7 and Table 2; Discussion limitations

Protection against MES-induced tonic hindlimb extension in male CF-1 mice: Acute oral dose-response; vehicle controls; estimated median effective dose, not a tested individual dose. — Results first paragraph; Fig. 2A

Protection against MES-induced tonic hindlimb extension in Sprague-Dawley rats of both sexes: Acute oral dose-response; vehicle controls; estimated median effective dose. — Results first paragraph; Fig. 2A

Mouse CBZ dose-response · Fig. 1A dose labels and group n; Fig. 2A ED50; Methods 4.1–4.3, Table 2

Rat CBZ dose-response · Fig. 1B dose labels and group n; Fig. 2A ED50; Methods 4.1–4.3, Table 2

Specifications

Manufacturer Adooq Bioscience
CAS Number 298-46-4
Formula C15H12N2O
Molecular Weight 236.27
Synonyms CBZ
SMILES
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 45 mg/mL (190.46 mM)
Water Insoluble
Ethanol 17 mg/mL (71.95 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Carbamazepine Research References

  1. [1] Xin Qiao, Guangchun Sun, Jeffrey J Clare, et al. Properties of human brain sodium channel α-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine British Journal of Pharmacology (2014). PMID: 24283699 DOI: 10.1111/bph.12534 Source material
  2. [2] Sooyeon Jo, Bruce P Bean. Sidedness of Carbamazepine Accessibility to Voltage-Gated Sodium Channels Molecular Pharmacology (2014). PMID: 24319110 DOI: 10.1124/mol.113.090472 Source material
  3. [3] Luis Bettio, Girish Bankar, Celine M Dubé, et al. The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents International Journal of Molecular Sciences (2025). PMID: 40806162 DOI: 10.3390/ijms26157029 Source material

Publications

4 publications citing this product

  1. Jingyeong Shin, .et al. , Chemical Engineering Journal, 2023, December
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  3. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  4. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Added to your cart

View Cart Checkout
Loading...